JRCT ID: jRCT2071230094
Registered date:22/11/2023
Trastuzumab BS Specific Use Results Survey
Basic Information
| Recruitment status | Complete |
|---|---|
| Health condition(s) or Problem(s) studied | HER2 positive gastric cancer |
| Date of first enrollment | 19/11/2018 |
| Target sample size | 150 |
| Countries of recruitment | ,Japan |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | Safety: Adverse events Efficacy: tumor reduction effect, best overall effect |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | Not applicable |
|---|---|
| Age maximum | Not applicable |
| Gender | Both |
| Include criteria | HER2 positive gastric cancer |
| Exclude criteria | Not set: The following is set as a precaution when selecting patients. |
Related Information
| Primary Sponsor | / / / |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | |
| Secondary ID(s) | Nil known |
Contact
| Public contact | |
| Name | Tatsuo Haneji |
| Address | 1-1, MARUNOUCHI 2-CHOME, CHIYODA-KU, TOKYO 100-0005, JAPAN Tokyo Japan 100-0005 |
| Telephone | +81-8070218144 |
| tatsuo.haneji@nipponkayaku.co.jp | |
| Affiliation | NIPPON KAYAKU CO., LTD. |
| Scientific contact | |
| Name | / / / |
| Address | 1-1, MARUNOUCHI 2-CHOME, CHIYODA-KU, TOKYO 100-0005, JAPAN Tokyo Japan 100-0005 |
| Telephone | +81-8070218144 |
| tatsuo.haneji@nipponkayaku.co.jp | |
| Affiliation | / |